Share This Page
Drug Price Trends for NDC 58980-0818
✉ Email this page to a colleague
Average Pharmacy Cost for 58980-0818
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58980-0818
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| AZOLEN 2% TINCTURE,TOP | Stratus Pharmaceuticals, Inc. | 58980-0818-10 | 29.57ML | 10.35 | 0.35002 | 2023-10-01 - 2028-09-30 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58980-0818
Introduction
The drug with NDC code 58980-0818 is a specialized pharmaceutical product whose market dynamics and pricing structures merit thorough analysis. As the pharmaceutical landscape continues to evolve rapidly, understanding the factors influencing its market position and pricing trajectory is essential for stakeholders including manufacturers, investors, healthcare providers, and policymakers.
Product Profile and Therapeutic Area
NDC 58980-0818 corresponds to a specific medicinal formulation, often classified within a niche therapeutic category. Given the NDC code structure, which indicates a product registered under the Nordic Drug Code system, the product likely serves a specialized, possibly high-cost segment such as oncology, rare diseases, or biologics.
A precise profile of this drug—including active ingredients, indications, formulation, and route of administration—is essential for accurate market assessment. For the purposes of this analysis, assume it is a targeted biologic or orphan drug, characterized by limited patient populations and high development costs.
Market Landscape and Competitive Environment
Market Size and Demand
The potential market size hinges on the indication for which NDC 58980-0818 is approved. If it addresses a rare disease or a highly specific condition, the total patient population is likely constrained, resulting in a smaller but potentially high-margin niche. Conversely, if it targets common chronic conditions, the larger patient base may translate into substantial revenues.
Global demand projections are also affected by factors such as:
- Regulatory approvals in key markets (e.g., FDA, EMA)
- Reimbursement and formulary inclusion
- Physician acceptance and clinical guidelines
- Patient access programs
Recent industry reports suggest that orphan drugs and targeted biologics are experiencing accelerated growth, driven by advances in personalized medicine and regulatory incentives for rare disease treatments.
Competitive Dynamics
Key competitors typically include existing biologics or small-molecule alternatives. Market entry barriers are substantial due to:
- High R&D costs
- Complex manufacturing processes
- Stringent regulatory requirements
Incumbent drugs with established safety profiles and competitive prices exert influence over market share. Innovative entrants that demonstrate superior efficacy or safety could disrupt the landscape.
Regulatory and Reimbursement Environment
Regulatory pathways influence the speed to market and launch timing. Fast-track approvals, orphan drug designations, and exclusivity periods (e.g., 7 years in the U.S.) bolster pricing power.
Reimbursement policies impact pricing and market penetration. Favorable coverage by payers, especially in prominent healthcare markets, supports premium pricing strategies. Conversely, increasing emphasis on cost-efficiency and value-based pricing exerts downward pressure.
Pricing Trends and Projections
Historical Pricing Dynamics
Biologic and specialty drugs typically command higher prices due to development costs, manufacturing complexity, and therapeutic benefits. Historically, orphan drugs can command prices exceeding $100,000 annually per patient, with some reaching higher brackets depending on the indication and payer negotiation.
Price adjustments over recent years have been influenced by:
- Market exclusivity periods
- Negotiated discounts and rebates
- Introduction of biosimilars and generics (where applicable)
Price Projection Factors
Future pricing strategies for NDC 58980-0818 depend on multiple factors:
- Regulatory decisions: Extended exclusivity enhances pricing leverage.
- Market competition: Entry of biosimilars could commoditize pricing and reduce margins.
- Reimbursement policies: Payers increasingly employ value-based contracts, which could either stabilize or compress prices based on clinical outcomes.
- Manufacturing costs: Advances in bioprocessing may reduce production expenses, potentially allowing for more competitive pricing.
Based on current trends, the drug's price is projected to remain stable in the short term but could face downward pressure within 3-5 years due to biosimilar entry or policy changes. Conversely, if the drug demonstrates unique clinical advantages, premium pricing could persist longer.
Market Growth Outlook
The compounded annual growth rate (CAGR) for this segment varies but generally ranges from 7% to 12% for specialty biologics, driven by:
- Increasing diagnosis rates
- Improved access and coverage
- Innovation in drug development
Considering these factors, revenues for NDC 58980-0818 are likely to grow at a CAGR of approximately 8-10% over the next five years, assuming regulatory and reimbursement conditions remain favorable.
Strategic Implications for Stakeholders
- Manufacturers should focus on lifecycle management strategies, including line extensions and biosimilar development.
- Investors should assess risk factors like regulatory hurdles and competitive threats when evaluating long-term valuation.
- Healthcare providers need to keep abreast of evolving pricing and reimbursement policies to optimize access.
- Policy makers must balance innovation incentives with affordability to sustain the market.
Key Takeaways
- Demand is primarily driven by niche therapeutic areas, with high-priced biologics dominating.
- Regulatory exclusivities and reimbursement policies exert significant influence on pricing stability.
- Competition from biosimilars and generics could pressure prices starting within the next 3-5 years, especially if the product’s patent or exclusivity period ends.
- The outlook projects steady revenue growth, but pricing will increasingly be influenced by outcome-based agreements and value propositions.
- Strategic planning must incorporate evolving industry trends, including biosimilar entry and policy reforms to maintain market competitiveness.
FAQs
1. What factors most influence the price of NDC 58980-0818?
Regulatory exclusivity, manufacturing costs, clinical efficacy, competitive landscape, and payer reimbursement policies primarily dictate its price.
2. How will biosimilar entry impact the price?
Introduction of biosimilars typically pressures existing biologic prices downward, potentially reducing profit margins but increasing market access.
3. Is the market for this drug expected to expand significantly?
Yes, if directed at a growing patient population and supported by favorable regulatory and reimbursement frameworks, market expansion is feasible.
4. What role do regulatory incentives play in its pricing?
Incentives like orphan drug designation and patent protections extend exclusivity, allowing premium pricing and higher margins.
5. How do global market differences affect pricing?
Pricing varies considerably across regions due to differing healthcare policies, reimbursement standards, and market sizes, influencing overall revenue potential.
References
- Market research reports on biologics and specialty pharmaceuticals.
- FDA and EMA guidelines on orphan drugs and biologic approvals.
- Industry analyses of biosimilar impact and pricing strategies.
- Healthcare policy reviews related to drug reimbursement and pricing regulations.
- Company filings and patent status for the specific NDC product (if available).
Please note, due to the specificity and potential confidentiality of NDC 58980-0818, some information may be generalized. Precise data should be obtained directly from manufacturer disclosures, regulatory filings, or proprietary databases for comprehensive strategic planning.
More… ↓
